Hypertension study to examine new recommended low for systolic BP levels.
A healthy blood pressure has long been associated with decreased risk of certain diseases. Now, researchers have been issued a grant to investigate whether lowering systolic blood pressure numbers below the currently recommended level could reduce the rate of cardiovascular disease (CVD), kidney disease and slow cognitive decline.
Case Western Reserve University School of Medicine received a $14.7 million, nine-year contract from the National Institutes of Health (NIH) to lead the trial called SPRINT (Systolic Blood Pressure Intervention Trial). The team comprises investigators from Case Western University and six other Northeast Ohio clinical centers under the umbrella of a Clinical Center Network. Lead investigator is Jackson T. Wright Jr., MD, PhD, professor of medicine at Case Western and director of the Clinical Hypertension Program at University Hospitals Case Medical Center.
The SPRINT study comprises more than 9,000 participants, aged 55 or older, with systolic blood pressure of at least 130 mmHg. All participants have a history of cardiovascular disease or are at high risk for heart disease by having at least one additional risk factor (except diabetes). Another criteria was that 40 to 50 percent of participants had chronic kidney disease. Blacks and other minorities comprise at least 40 percent of the study.
The results of this study will increase the small body of evidence surrounding this hypothesis. It is hoped that the findings will be used to reevaluate the optimal blood pressure for patients and have the potential to establish new guidelines for health care providers.
While studies take time to show evidence, RESPeRATE has already been clinically proven in 10 separate trials, to effectively lower hypertension. RESPeRATE is also the first completely natural medical device to be clinically approved. It has also been passed by the FDA. The device involves no medication or visits to a clinic for treatments. It is already used by more than 250,000 men and women worldwide to lower hypertension naturally.
The clinical studies on RESPeRATE have been published in numerous peer-reviewed publications including The American Journal of Hypertension and the American Heart Association Hypertension Primer.